Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Item

http://www.wikidata.org/entity/Q34566004

Q34566004

about

Abatacept for rheumatoid arthritis Biologic interventions for fatigue in rheumatoid arthritis A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics Abatacept: the evidence for its place in the treatment of rheumatoid arthritis.Decision tool to improve the quality of care in rheumatoid arthritis The efficacy and safety of abatacept in rheumatoid arthritis.Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).Translating co-stimulation blockade into clinical practice.Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis New and emerging therapies for the treatment of rheumatoid arthritis.A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.Abatacept for the treatment of rheumatoid arthritis: A review.Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis.Abatacept: a review of its use in the management of rheumatoid arthritis.Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis Health-related quality of life in Moroccan patients with rheumatoid arthritis.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures.Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.Abatacept in the treatment of rheumatoid arthritis.Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate

P2860

Q24240131-F358E4E9-F8B1-4476-8D26-220F46E138BA Q26471538-4230314C-20F9-4B79-B5EA-93F5252434CF Q26770099-65F4EFA6-017C-4806-86F5-54F8B2FC5E7D Q33725521-FDC6D721-4817-4E87-9AC0-E20C26720F03 Q33809045-BDE20524-FC63-4EB2-BADB-DB79BD9A464C Q34449851-3F2B0C2C-FD58-47A4-A13C-D5231E66C093 Q36032715-6A4E104F-1148-4EA9-B4F9-D9D5E9122AFB Q36059373-143866D9-4038-4B0D-8B62-9B3461E28E69 Q36252760-F08FFD00-C587-4300-BE8F-233D1B73F0D6 Q36796741-D3AD391D-28F5-4548-8556-30686DC4C48E Q36972500-18458D4B-3A65-49C1-A5C4-D6727CC5A6B8 Q37015967-509BE2E0-4C35-41A0-B3B6-7F4902ACFA7A Q37032656-E4D9CCD0-D5E4-43C6-A614-974FF56FD9F1 Q37301126-5E64B59B-1EB5-4BB0-8BE8-C6BFE8F19128 Q37358229-30C67F1E-A416-4821-B446-0E089F25523C Q37600477-054F39E1-569B-4E1A-BE17-69F95F063F48 Q37633537-8CBE6AB1-520B-47D8-AA94-B70E2B9153D0 Q37672814-38DCFF2D-1785-457F-96E3-3A8000A1AC9C Q37701273-69173DD1-1359-4EB5-8443-A11FA90C5C73 Q38116472-1B6D0775-D2FE-4E58-B757-21E240DB2D44 Q38182440-7A3DEB3C-B368-4332-A920-82A63CFA6B5E Q38993229-0C2C2BF8-0B6C-43B4-A3DD-20BBF9BD74CF Q39091646-97CE275F-20E8-460D-8975-3F1D0731C463 Q39230189-9CE1E1E6-F944-489E-95DB-D47E15BD3509 Q40795254-6E626F12-B9A4-43FB-A191-C3BC46122F13 Q41206422-EB814317-413E-4936-9D5D-FA0A0E7153B0 Q41905727-BDEEA2A1-D9C2-4EDE-9DC7-1133D5043069 Q45982095-FC2B36B0-FC18-442D-AC2A-BEEFDDDB4DDB Q48089791-0C5DF1CF-5B99-4E8E-AE18-75523A26839E Q51835868-EFF5AAFC-EDFB-401C-B801-A5417AF7677F Q58204734-DC3F9E36-60A0-4AA0-9682-35E548836D4D

P2860

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Item

http://www.wikidata.org/entity/Q34566004

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu